Whalesbook
Record Annual Revenue, Q4 Profit Takes a Hit
Cipla's stock surged nearly 5% on Wednesday, May 13, reaching ₹1,353.80 on the NSE. The jump followed the company's announcement of its highest-ever annual revenue: ₹28,163 crore for fiscal year 2026, up 2.23% from the previous year. However, the fourth quarter of FY26 told a different story. Revenue dipped 2.8% to ₹6,541 crore, and net profit after tax fell sharply by 54.6% to ₹555 crore compared to the same period last year. EBITDA also dropped 35.17% to ₹997 crore, leading to a significant decrease in EBITDA margins from 22.8% to 15.2% in Q4 FY26. This contrast between strong full-year results and a weak quarter raises questions about Cipla's future profitability.
Valuation Snapshot: Discount to Peers
Cipla's Price-to-Earnings (P/E) ratio is currently around 23.02x-23.7x. This places Cipla at a valuation discount compared to competitors like Sun Pharmaceutical Industries (35-40.66x P/E) and Dr. Reddy's Laboratories (17.5x-25.26x P/E). The Indian pharmaceutical sector average P/E is 33.86x. This discount might indicate that the market expects slower growth or sees specific risks for Cipla. The company's Relative Strength Index (RSI) is neutral, around 48-60.60. Meanwhile, the Indian pharmaceutical market is expected to grow robustly, with an 8.1% CAGR forecast from 2026 to 2033, particularly in chronic therapies like cardiovascular and diabetes medicines. Cipla is well-positioned in these areas.
Profitability Concerns and Stock Performance
The sharp drop in Q4 profits and tighter EBITDA margins raise concerns about Cipla's short-term operational efficiency and pricing power. While the company points to its core businesses for full-year success, the quarterly decline is significant. Cipla has a history of facing regulatory issues with its US manufacturing sites, impacting drug approvals. Management is working on these matters, but it remains a risk. Competitively, despite leading in some chronic therapy areas, Cipla's revenue and profits trail larger players like Sun Pharma. The company's stock is down about 14.5% year-to-date, lagging the Nifty50 index. Over the past year, Cipla's stock has fallen 14.51%, underperforming Sun Pharma and Dr. Reddy's Laboratories' positive 6% return. Recent downgrades to FY26 EPS forecasts also add caution.
Outlook and Analyst Views
Management plans to continue expanding key markets, investing in its future pipeline, and addressing regulatory issues. Achin Gupta, appointed MD & GCEO in April 2026, has a strong background leading Cipla's Indian operations. Analysts currently rate Cipla as 'Neutral' with an average 12-month price target of ₹1,431.22, indicating about 10% potential upside. However, recent downward revisions in earnings forecasts suggest caution is needed as Cipla deals with margin pressures and regulatory challenges.